13. Multiple sclerosis/Neuromyelitis optica
3,050 clinical trials,   2,147 drugs   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2006-003384-30-SK
(EUCTR)
26/02/200708/11/2006A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for Multiple SclerosisA Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for Multiple Sclerosis Multiple SclerosisProduct Name: NeuroVax 300ug/mL Dose for IM Injection
Product Code: IR902
Other descriptive name: VB6S5
Other descriptive name: VB13S1
Other descriptive name: VB5S2
The Immune Response CorporationNULLNot RecruitingFemale: yes
Male: yes
200Phase 2Slovakia